2024 |
Levi Strauss & Co. - Ordinary Shares Cls A
|
Independent Director |
285.6 K |
- |
2023 |
Revance Therapeutics Inc
|
Independent Director |
317.5 K |
6.0 % |
2023 |
Levi Strauss & Co. - Ordinary Shares Cls A
|
Independent Director |
- |
- |
2022 |
Revance Therapeutics Inc
|
Independent Director |
299.5 K |
0.3 % |
2022 |
Levi Strauss & Co. - Ordinary Shares Cls A
|
Independent Director |
278.2 K |
1.4 % |
2021 |
Revance Therapeutics Inc
|
Independent Director |
298.6 K |
1.3 % |
2021 |
Levi Strauss & Co. - Ordinary Shares Cls A
|
Independent Director |
274.3 K |
20.8 % |
2020 |
Revance Therapeutics Inc
|
Independent Director |
294.9 K |
24.5 % |
2020 |
Levi Strauss & Co. - Ordinary Shares Cls A
|
Independent Director |
227.0 K |
-14.7 % |
2019 |
Levi Strauss & Co. - Ordinary Shares Cls A
|
Independent Director |
266.1 K |
8.4 % |
2019 |
Revance Therapeutics Inc
|
Independent Director |
236.8 K |
- |
2018 |
Levi Strauss & Co. - Ordinary Shares Cls A
|
Independent Director |
245.4 K |
- |